Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Anti-inflammatory Medications in CF May Help Reduce Lung Bacteria

A new study suggests that the use of anti-inflammatory medications to modulate immune signaling proteins in people with cystic fibrosis (CF) may potentially reduce bacteria and avoid antibiotic resistance. Researchers found that different bacteria in the airways of CF patients induced the release of varying signaling proteins, called cytokines,…

Early Childhood Weight Linked to Later Lung Function

Higher weight in children with cystic fibrosis (CF) at 1 year of age, and increasing weight gain from ages 1 through 5, were correlated significantly with better lung function at age 6, according to an analysis of two large  registries. Current guidelines may need to be updated to encourage…

Reducing Treatment Burden Key to CF Patients, Survey Suggests

Adults with cystic fibrosis (CF) are willing to accept reductions in lung function and life expectancy as a trade-off for a reduced treatment burden, a survey of patient preferences suggested. Over all other outcomes, the participants preferred a treatment choice that would extend their life expectancy by 10 years…

Mothers of CF Children Need Support for Caregiver Burnout: Study

Mothers who care for children with cystic fibrosis (CF) often experience depression, burnout, caregiver burden, and negative attitudes toward their children, a study suggests. These caregiving struggles may increase with more hospital visits and hospitalizations, and having a lower family income, more children, and another child with a chronic…

ASO Cocktail May Help in Treating CF Due to W1282X Mutation

A potential gene-specific therapy for cystic fibrosis (CF) may lie in antisense oligonucleotides, or ASOs, that enhance the production and activity of the truncated CFTR protein caused by the W1282X mutation, a cell study suggested. In combination with approved CFTR modulator therapies, candidate ASOs were seen to raise CFTR-W1282X…

Cincinnati Children’s Gains AI Platform to Speed CF Research

Cincinnati Children’s Hospital Medical Center will use Epistemic AI’s platform, a state-of-the-art artificial intelligence (AI) research tool for the life sciences, to augment its research into cystic fibrosis (CF) and other lung conditions. The Boomer Esiason Foundation (BEF) venture philanthropy initiative helped bring this capability to scientists at Cincinnati…

MS Therapy Boosts Tobramycin’s Effectiveness Against P. aeruginosa

Glatiramer acetate, an approved multiple sclerosis (MS) therapy, improved the effectiveness of the antibiotic tobramycin against Pseudomonas aeruginosa, a type of bacteria that commonly infects the lungs of people with cystic fibrosis (CF), a study demonstrated. The findings support glatiramer acetate as a promising antibiotic add-on therapy candidate,…